Cue Biopharma ^{Priced, Nasdaq: CUE}

We are an innovative biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. While currently in preclinical development, we believe our CUE Biologics platform provides a potentially transformative solution to the challenges facing prevailing immunotherapeutics. We believe we are uniquely positioned to become a prominent and leading player in immuno-oncology, immunotherapy and autoimmune disease. Our platform is intended to allow us to efficiently design and develop drug candidates that specifically and selectively engage and modulate disease relevant T cells, providing therapeutic advantages while minimizing or eliminating the unwanted side effects. Licensing technology from the Albert Einstein College of Medicine, our portfolio includes our core technology platform for the engineering of biologics to selectively control T cell activity ("CUE Biologics"), a growing portfolio of precision immuno-modulatory drug candidates, and two supporting technologies we call MOD and viraTope that enable the discovery of costimulatory signaling molecules (ligands) and T cell targeting peptides, respectively.